SWM
SGMO

Shelton Wealth Management’s SANGAMO THERAPEUTICS INC SGMO Stock Holding History

Shelton Wealth Management’s Portfolio SGMO Stock Details SGMO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q2 		– Sell
-28,000
Closed -$18.4K – 175
2025
Q1 		$18.4K Hold
28,000
– – 0.01% 134
2024
Q4 		$28.6K Buy
+28,000
New +$51.2K 0.01% 139

Other funds holding SGMO

YAG
Yorkville Advisors Global Mountainside, New Jersey $155M AUM 58.46% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
WA
Wasatch Advisors Salt Lake City, Utah $15.3B AUM 25.06% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
GCP
GSA Capital Partners London, United Kingdom $1.61B AUM 28.28% 1-Year Est. Return
Charles Schwab
Charles Schwab San Francisco, California $654B AUM 26.35% 1-Year Est. Return
IC
Ikarian Capital Dallas, Texas $1.23B AUM 600.17% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return

Shelton Wealth Management's SGMO Position: Q2 2025 in Review

Shelton Wealth Management sold out of SANGAMO THERAPEUTICS INC (SGMO) in Q2 2025, closing a stake of 28,000 shares — an estimated $18.4K sold.

Shelton Wealth Management first reported a position in SGMO in Q4 2024 and held it in 2 quarters. The position peaked at $28.6K in Q4 2024. 114 funds tracked by Wall St. Rank hold SGMO as of Q2 2025.

  • Shelton Wealth Management reported no remaining SANGAMO THERAPEUTICS INC position as of Q2 2025 after selling out during the quarter.
  • Shelton Wealth Management sold 28,000 SANGAMO THERAPEUTICS INC shares in Q2 2025, an estimated $18.4K.
  • Shelton Wealth Management first reported a position in SANGAMO THERAPEUTICS INC in Q4 2024 and held it in 2 quarters.
  • Shelton Wealth Management's SANGAMO THERAPEUTICS INC position peaked at $28.6K in Q4 2024.
  • 114 funds tracked by Wall St. Rank held SANGAMO THERAPEUTICS INC as of Q2 2025.

Based on Shelton Wealth Management's 13F filing for Q2 2025, filed 11 Jul 2025.